RANDOMIZED, CONTROLLED, OPEN TRIAL OF TWO STANDARDIZED DECLINE SCHEMES, FAST (NORTH AMERICAN) AND SLOW (EUROPEAN) RESPECTIVELY, OF CORTISONE IN GIANT CELL ARTERITIS
This research is looking at Giant Cell Arteritis (GCA), sometimes called Horton's disease, which is a condition where blood vessels become inflamed. People with GCA are often treated with steroid medications like prednisone. This study compares two different ways of gradually lowering the dose of these steroids in patients. One method is a quicker reduction, similar to what's common in North America, and the other is a slower reduction, as often used in Europe. The main goal is to see which approach helps more patients stay completely free of their symptoms for a year (52 weeks) without the disease flaring up again. Researchers will also be tracking if symptoms return, how long it takes, and checking for any side effects from the medication. This will help doctors understand the best way to manage GCA treatment.
At a glance
What is this study about?
This study is designed to help us understand the best way to treat Giant Cell Arteritis (GCA). GCA is a condition where the blood vessels, especially those in the head and neck, become inflamed. This can cause headaches, changes in vision, and tenderness in the scalp. Steroid medications, like prednisone, are very effective at controlling GCA, but they need to be reduced slowly over time.
The researchers want to compare two different ways of gradually reducing the steroid dose. One way is a bit faster, like some doctors use in North America, and the other is slower, similar to how doctors might do it in Europe. The main aim is to see which of these two approaches helps more patients stay well and free from their GCA symptoms for a full year without the disease flaring up again.
By comparing these two methods, doctors hope to find a clearer guideline for how to best reduce steroid medication for GCA patients. This could lead to better outcomes for people living with this condition, helping them stay in remission while also reducing potential side effects from long-term steroid use.
Key takeaways
- This study compares two ways to gradually reduce steroid medication for Giant Cell Arteritis.
- The goal is to find out which method helps patients stay symptom-free for longer.
- You would receive prednisone and have regular health checks for up to a year.
- Researchers will monitor for symptoms returning and any medication side effects.
- Participants must be adults diagnosed with Giant Cell Arteritis.
Who may be eligible?
To be considered for this study, you need to be an adult, aged 18 or over. This study welcomes both men and women.
The main requirement is that you have Giant Cell Arteritis (also known as Horton’s disease). This study is for people who have been diagnosed with this specific condition.
Other details about your health will be checked to make sure the study is a good fit for you and safe. Your doctor can help determine if you meet all the specific criteria.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a confirmed diagnosis of Giant Cell Arteritis?
- Are you able to attend regular appointments for check-ups and tests?
- Are you willing to follow a specific medication reduction plan?
- Are you comfortable with the potential risks and benefits of participating in a study?
What does participation involve?
If you join this study, you will be assigned to one of two groups. Each group follows a different plan for how your steroid medication (prednisone) will be slowly reduced over time. One plan takes about 28 weeks, and the other takes about 52 weeks.
You will take the study medication, which is prednisone in various strengths. Throughout the study, which could last up to a year, you will have regular check-ups. These appointments will involve blood pressure and weight checks, blood tests to monitor sugar levels and other important markers, and bone density scans at the beginning, at 28 weeks, and at 52 weeks.
The research team will closely monitor you for any signs of your GCA symptoms returning, or for any side effects from the medication. Your total participation duration will depend on which treatment plan you are assigned to, either 28 or 52 weeks, plus any follow-up appointments.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is Giant Cell Arteritis?
It's a condition where arteries (blood vessels) become inflamed, often affecting those in the head and neck. It's also known as Horton's disease.
What kind of medication will I take?
You will take prednisone, which is a type of steroid medication, in specifically prescribed doses.
How long will the study last?
The study will last either 28 weeks (about 7 months) or 52 weeks (about a year), depending on which treatment group you are in.
What does 'remission without relapse' mean?
It means your GCA symptoms are gone and you haven't had any flare-ups or return of the disease during the study period.
Will I have to pay to join the study?
Clinical trials do not typically charge participants to take part. All study-related medication and tests would be provided as part of the research.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.